Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 drug interaction study with midazolam in healthy volunteers
NCT05550636Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nerandomilast, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 24 hours and Maximum Measured Concentration of Midazolam in Plasma at 24 hours. Started Oct 2022; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT05550636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05550636.